Search clinical trials for: avelumab

Total 282 results

Johannes Gutenberg University Mainz
Merck KGaA, Darmstadt, Germany

Completed

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy (AveNEC)

Cancer

Germany
Pfizer

Completed

A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)

Renal Cell Cancer

United States, United Kingdom, Japan
Guru Sonpavde
Pfizer; Hoosier Cancer Research Network

Withdrawn

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Kidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney Carcinoma

United States
Pfizer

Terminated

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Pancreatic Cancer

Belgium, United States, Singapore
Radboud University Medical Center
Merck KGaA, Darmstadt, Germany

Completed

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (PINNACLE)

Non Small Cell Lung Cancer

Netherlands
Icahn School of Medicine at Mount Sinai

Completed

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Glioblastoma | GBM

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Solid Tumors

United States, Korea, Republic of, Taiwan, France, United Kingdom, Belgium, Czechia, Germany, Poland
National Cancer Institute (NCI)

Terminated

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Colorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Colorectal Adenocarcinoma

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase I/II Study of Avelumab in Pediatric Cancer Subjects

Lymphoma | Refractory or Relapsed Solid Tumors

Korea, Republic of, United States, Canada, Belgium, Denmark
4SC AG
Merck KGaA, Darmstadt, Germany

Withdrawn

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

Merkel Cell Carcinoma
National Cancer Institute (NCI)

Completed

Avelumab for People With Recurrent Respiratory Papillomatosis

Human Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory Papillomatosis | Juvenile Laryngeal Papilloma

United States
Megan Daly, MD
EMD Serono

Completed

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
University of Birmingham
Pfizer; Bloodwise

Completed

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma (AVAIL-T)

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

United Kingdom
Presage Biosciences
Northwell Health; Oregon Health and Science University; University of Washington and other collaborators

Completed

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Soft Tissue Sarcoma Adult

United States
Samsung Medical Center
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Lymphoma, Extranodal NK-T-Cell

Korea, Republic of
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
National Taiwan University Hospital

Enrolling by invitation

The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma

Metastatic Esophageal Squamous Cell Carcinoma | Esophageal Tumor

Taiwan
Hospices Civils de Lyon

Completed

Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (TROPHIMMUN)

Gestational Trophoblastic Neoplasias (GTN)

France
University of Leipzig
Abbott Medical Devices; Leipzig Heart Institute GmbH; Zentrum für Klinische Studien...

Completed

Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease (CAT-PVC)

Heart Diseases | Cardiomyopathies | Ventricular Premature Complexes

Germany
National Cancer Institute (NCI)

Terminated

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Cancer | Cancer of Pancreas

United States
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
Johns Hopkins University

Completed

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Cutaneous Toxicity From ICI Therapy

United States
National Cancer Institute (NCI)

Terminated

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Myeloma, Multiple | Myeloma-Multiple

United States
Andrew Sharabi
Pfizer

Terminated

Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

Early Stage Non-Small Cell Lung Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Chordoma | Unresectable Malignant Neoplasm

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Merkel Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Metastatic Pancreatic Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Ovarian Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma Recurrent

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Non Hodgkin Lymphoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
Seoul National University Hospital
Merck KGaA, Darmstadt, Germany

Completed

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment (AvelumabHCC)

Carcinoma, Hepatocellular

Korea, Republic of
Andrew J. Armstrong, MD

Completed

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC)

Prostate Cancer

United States
Universitair Ziekenhuis Brussel

Completed

Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (myDAvIpNi)

Solid Tumor | Metastases to Soft Tissue

Belgium
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) (COMBO)

Advanced Solid Tumors

Spain, United States, Netherlands, Hungary, Italy, France, Belgium
Pfizer
EMD Serono

Terminated

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (Javelin DLBCL)

Diffuse Large B-Cell Lymphoma

United States, Belgium, United Kingdom, Spain, Australia, Korea, Republic of, Italy, Poland
Pfizer

Completed

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

Neoplasms

United States, Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Ovarian Cancer

Belgium, United States, United Kingdom
University of Texas Southwestern Medical Center
AstraZeneca

Terminated

Anti-PD-L1 and SAbR for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Recurrent Epithelial Cancer of Ovary

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients (AVEVAC)

Colorectal Carcinoma

Spain
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

Solid Tumors

Germany
Pfizer

Completed

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Carcinoma, Hepatocellular

Japan

Search clinical trials for: avelumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations